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Background: With the advances in high throughput technologies, increasing amounts of cancer somatic mutation
data are being generated and made available. Only a small number of (driver) mutations occur in driver genes and
are responsible for carcinogenesis, while the majority of (passenger) mutations do not influence tumour biology. In
this study, SomInaClust is introduced, a method that accurately identifies driver genes based on their mutation
pattern across tumour samples and then classifies them into oncogenes or tumour suppressor genes respectively.
Results: SomInaClust starts from the observation that oncogenes mainly contain mutations that, due to positive
selection, cluster at similar positions in a gene across patient samples, whereas tumour suppressor genes contain a high
number of protein-truncating mutations throughout the entire gene length. The method was shown to prioritize driver
genes in 9 different solid cancers. Furthermore it was found to be complementary to existing similar-purpose methods
with the additional advantages that it has a higher sensitivity, also for rare mutations (occurring in less than 1% of all
samples), and it accurately classifies candidate driver genes in putative oncogenes and tumour suppressor genes. Pathway
enrichment analysis showed that the identified genes belong to known cancer signalling pathways, and that the
distinction between oncogenes and tumour suppressor genes is biologically relevant.
Conclusions: SomInaClust was shown to detect candidate driver genes based on somatic mutation patterns of
inactivation and clustering and to distinguish oncogenes from tumour suppressor genes. The method could be used for
the identification of new cancer genes or to filter mutation data for further data-integration purposes.
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Carcinogenesis is a multi-step process caused by the accu-
mulation of somatic mutations (point mutations or gen-
omic copy number variations). These so-called driver
mutations lead to a selective growth advantage of affected
cells, resulting in positive selection and clonal expansion
[1-3]. Driver mutations occur in cancer (driver) genes,
which are involved in cell proliferation, differentiation and
apoptosis. A distinction is made between oncogenes
(OGs) and tumour suppressor genes (TSGs). OGs lead to
a growth advantage when they become constitutively ac-
tive due to gain-of-function mutations. For TSGs this* Correspondence: kathleen.marchal@intec.ugent.be
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article, unless otherwise stated.growth advantage is explained by inactivation of the gene
as a result of loss-of-function or protein-truncating muta-
tions (nonsense mutations and frameshift insertions or de-
letions) [4,5].
However, driver mutations only represent a minority
of the total number of mutations that are present in a
malignant tumour [3]. Indeed, most mutations that are
found in (cancer) cells are random events that do not
lead to growth advantages. These mutations are known
as passenger mutations. While it is estimated that the
development of a malignant tumour implies between 5
to 8 driver mutations, a median number of 33 to 66 mu-
tations are found in most solid tumours, from which the
majority are passenger mutations [1]. With the increas-
ing number of whole genome and exome data made
available via initiatives like TCGA and ICGC [6,7], dis-
tinguishing driver mutations from passenger mutationsd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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portant for the identification of novel cancer genes as
such, but also because a lot of the currently available
data-integration methods depend on a reliable filtering
of somatic mutations.
This filtering is often frequency-based, i.e. the analysis
is restricted to genes that are mutated in a minimal pro-
portion of all samples (e.g. 2%) [8-10]. However, this ap-
proach implies that non-frequently mutated genes will
be discarded and crucial information might get lost for
further analysis. On the other hand it is well-known that
some genes that are not involved in carcinogenesis (e.g.
TTN) might be frequently mutated and hence will be se-
lected by a naïve frequency-based filtering method [11].
Therefore, several driver gene prioritization methods have
been developed recently that search for signs of positive
selection across a cohort of tumours to identify candidate
driver genes [12]. Methods like MutSig(CV) [11], MuSiC
[13] and OncodriveClust [14] detect genes that are mu-
tated more frequently than expected from a calculated
background mutation rate, while methods like Oncodri-
veFM [15] and ActiveDriver [16] assess the expected func-
tional impact to identify putative driver genes. However,
these approaches are in general not capable of detecting
less frequently mutated genes, nor do they distinguish be-
tween OGs and TSGs.
Vogelstein et al. suggested a ratiometric method (or
“20/20 rule”) to detect driver genes and distinguish be-
tween OGs and TSGs [1]. This method is based on the
assumption that in OGs at least 20% of the mutations
are missense mutations that cluster at recurrent posi-
tions across different tumour samples, whereas for TSGs
at least 20% of the observed mutations are protein-
truncating mutations which occur throughout the entire
gene length. To be classified as an oncogene, an arbi-
trary threshold of 10 clustering mutations was required
and the classification of tumour suppressor genes im-
plied a minimal number of 7 inactivating mutations.
Furthermore the scores assigned to the different genes
cannot be interpreted statistically and the method re-
quires additional manual curation for its application [1].
To solve these issues we have developed SomInaClust,
which builds on the basic concept of Vogelstein’s
method. The method uses a large reference mutation
database to 1) determine mutational hot spots, i.e. CDS
(coding DNA sequence) positions that contain more
mutations across samples than could be expected
purely by chance and 2) calculate the gene-specific
background mutation rate. This information is subse-
quently used to determine candidate driver genes in a
specific set of mutation data, based on the mutation
pattern that is observed in each gene across tumour
samples. SomInaClust was able to accurately prioritize
driver genes in 9 different solid cancers and alloweddistinguishing OGs from TSGs in these tumours, even
for genes that have a low mutation frequency.
Methods
Overview of SomInaClust
SomInaClust identifies candidate driver genes from
whole exome or genome mutation data based on their
mutation patterns. The basic assumption is that, due to
selective pressure, driver genes are characterized by 1)
clustering mutations and/or 2) a high number of inacti-
vating (protein-truncating) mutations across tumour
samples. Whereas the former is the main pattern ex-
pected for OGs, the latter is the main pattern for TSGs.
Because of this association, inactivating mutations (i.e.
nonsense mutations and frameshift indels) are further
referred to as TSG mutations and other mutations (i.e.
missense mutations and in-frame indels) are referred to
as OG mutations. The method follows a two-step ap-
proach (Additional file 1: Figure S1).
In the first or reference step the background mu-
tation rate is estimated for each gene and hot spots
(i.e. gene positions where mutations tend to cluster
across tumour samples) are identified in a reference
mutation database (Additional file 1: Figure S1). In
this study the COSMIC database was used for this
purpose [17].
Mutation rates are known to vary widely throughput
the genome [18]. To correct for this mutational hetero-
geneity, two gene-specific correction factors are calcu-
lated. This calculation starts from the simplifying
assumption that mutations have an equal occurrence
probability and that silent mutations are not under se-
lective pressure. Starting from 61 different non-stop co-
dons, each with 9 possible mutations (i.e. 3 for each
nucleotide), 549 different mutations can theoretically
occur. From those 549 mutations, 392 can be classified
as missense, 23 as nonsense and 134 as silent mutations
(Additional file 2: Table S1). Assuming an equal muta-
tion probability, a ratio of 134/392 silent-to-missense
mutations (i.e. for each 392 missense mutations, 134 si-
lent mutations are to be expected) and 134/23 silent-to-
nonsense mutations would be expected. By comparing
for each gene the observed ratios to these expected ra-
tios, two gene-specific correction factors are defined:
− OG correction factor : 1−
observed ratio
expected ratio
¼ 1−
Nsil

NOG
134
392=
− TSG correction factor : 1−
observed ratio
expected ratio
¼ 1−
Nsil

NTSG
134
23=
with Nsil, NOG and NTSG being the total number of
observed silent mutations, OG mutations and TSG mu-
tations in a gene across tumour samples. When the
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pected ratio), they are put to zero. By now multiplying,
for each analysed gene the observed number of OG or
TSG mutations with these gene-specific correction fac-
tors, mutations are corrected for different background
mutation rates. Genes that contain a high number of
mutations due to a high background mutation rate will
have a correction factor close to zero (number of silent
mutations will be proportionally increased). In these
genes OG or TSG mutations are expected to be rather
non-specific. This low correction factor will decrease
the weight of these mutations. Genes that contain a high
number of mutations due to positive selection will have
a correction factor close to one, meaning a higher
weight of the mutations.
Subsequently, for each gene the mutational hot spots
are determined. A hot spot corresponds to any CDS nu-
cleotide position for which at least k OG mutations are
observed across samples and for which the probability
of observing this same number of k OG mutations by
chance is less than 0.05, given a total number of n OG
mutations and the gene’s CDS length. This can be calcu-
lated using a cumulative binomial test given by:
XkOG
1
nOG
kOG
 
pkOG−1l 1−plð ÞnOG−kOG≤0:05
Where pl = 1/CDS length, kOG = the number of clus-
tering OG mutations on the same nucleotide position
and nOG = the total number of observed OG mutations
in the gene across tumour samples (the latter two after
correction with the OG correction factor).
In the second or detection step the gene-specific OG
(pOG) and TSG (pTSG) random mutation probabilities
are determined (Additional file 1: Figure S1).
pOG is defined as the probability that kh random OG
mutations occur at hot spot locations (defined in the
first step), given a total number of n observed OG muta-
tions for a given CDS length. This can be calculated
using the following cumulative binomial test:
pOG ¼
XkhOG
1
nOG
khOG
 
pkhOGh 1−phð ÞnOG−khOG
Where ph = the probability for a random mutation to
occur in a hotspot, i.e. the number of hot spots/CDS
length. khOG = the number of OG mutations located at
hot spots and nOG = the total number of OG mutations
across tumour samples (both after correction with the
OG correction factor).
The same binomial test is used for the calculation of
pTSG, but instead of using the probability of a random
mutation to occur in a hotspot, the protein-truncatingmutation probability is used, as estimated from the non-
sense mutation probability:
pTSG ¼
XkTSG
1
ntot
kTSG
 
pkTSGn 1−pnð Þntot−kTSG
Where pn = the probability for a random mutation to
be a nonsense mutation, here defined as 23/549 (23 ways
for a non-stop codon to mutate in a stop codon out of
549 theoretically possible mutations, see Additional file
2: Table S1). kTSG = the number of TSG mutations and
ntot = the total number of mutations across tumour sam-
ples (both corrected using the TSG correction factor).
Next, a multiple testing correction of pOG and pTSG
using the Benjamini-Hochberg method is performed
[19]. From the corrected p values (qOG and qTSG), the
driver gene probability is calculated as follows: qDG =
qOG x qTSG. A putative driver gene is then defined as a
gene with qDG ≤ 0.05.
To classify predicted driver genes in respectively puta-
tive OGs or TSGs, two additional scores are defined: the
OG score and the TSG score. The OG score is the propor-
tion of (clustering) OG mutations to the total number of
OG mutations. Putative OGs are then defined as genes
with an OG score ≥20. In the same line the TSG score is
the proportion of TSG mutations to the total number of
mutations. Putative TSGs are then defined as genes with a
TSG score ≥20. When both the OG and the TSG scores
are ≥20, a gene is defined as a TSG (a specific missense
mutation can render a TSG inactive, but a truncating mu-
tation is rarely expected to overactivate a gene).
Comparison with other driver gene identification
algorithms
SomInaClust was compared with 3 alternative driver
gene identification methods that could be run starting
from the same maf (mutation annotation format) input
file as SomInaClust: MutSigCV 1.4 [11], OncodriveClust
[14] and OncodriveFM [15]. All algorithms were run in
default mode, following the instructions provided by the
developer.
MutSigCV was downloaded from http://www.broadin-
stitute.org/cancer/cga/mutsig and run following the in-
structions for the case where the analysis is based on the
maf file only. MutSigCV was run in Matlab R2013a.
OncodriveClust was downloaded from https://bitbucke-
t.org/bbglab/oncodriveclust/. The input files containing the
protein affecting and coding silent mutations (i.e. gene
names and amino acid positions) were generated from the
maf files that were used by all other algorithms in this
study. The input file containing the CDS length for the
gene transcripts was created after downloading the
HGNC (HUGO Gene Nomenclature Committee) gene
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tion from Biomart Ensembl.
OncodriveFM was downloaded from https://bitbucke-
t.org/bbglab/oncodrivefm. OncodriveFM requires 1 input
file containing, for each gene, 3 different functional impact
scores: Mutation Assessor (MA), SIFT and PolyPhen (PP2)
score. These scores were calculated using Annovar [20],
which was downloaded from http://www.openbioinforma-
tics.org/annovar/. Annovar input files were prepared using
the maf file that was used by all other algorithms in this
study. Missing MA, SIFT and PP2 were optimized using
the criteria of A Gonzalez-Perez and N Lopez-Bigas [15]:
2,1 and 0 for silent mutations and 3.5,0 and 1 for nonsense
or frameshift mutations.
COSMIC and TCGA data
Somatic mutation reference data were downloaded from
the COSMIC database on November 24, 2014 (v71) [21].
For the tumour-specific analysis, TCGA whole exome
data were used [6]. The maf files were downloaded from
the TCGA data portal on August 22, 2014. Only muta-
tion data, analysed using the Illumina GA DNASeq plat-
form and annotated using NCBI 37 (hg 19) were used
for analysis. Data from the following cancer types were
downloaded: bladder cancer (BLCA), breast cancer
(BRCA), colon cancer (COAD), glioblastoma multiforme
(GBM), head and neck squamous cell cancer (HNSC),
lung squamous cell cancer (LUSC), ovarian cancer (OV),
rectal cancer (READ) and uterine cancer (UCEC).
Cancer gene census (CGC) list
The cancer census gene list (v71) was downloaded from
COSMIC as a reference list for generally accepted can-
cer genes. This list is an ongoing effort to collect genes
that contain mutations that have been shown to be in-
volved in carcinogenesis [22]. It currently contains over
500 genes, including information on the molecular gen-
etics of the gene, i.e. whether the gene operates in a
dominant or in a recessive way. As OGs are expected to
be dominant (i.e. one gain-of-function mutation allelic
variant suffices for a growth advantage) and TSGs are
expected to be recessive (i.e. one loss-of-function can
still be compensated by the other allele) [4], this infor-
mation was used to estimate the OG/TSG classification
accuracy of the SomInaClust method.
Pathway enrichment analysis using KEGG data
Pathway enrichment analysis was performed to determine
the signalling pathways in which putative driver genes are
active. Pathway interaction data were downloaded from
KEGG (Kyoto Encyclopedia of Genes and Genomes [23])
on August 27, 2014 and pathway enrichment was deter-
mined by Fisher’s Exact Test with control of the false dis-
covery rate (q ≤ 0.05).Data preprocessing and statistical analysis
The R statistical package was used for all data processing
and statistical analysis, including the implementation of
the SomInaClust method.
All gene names/symbols from all files used in this study
(e.g. Cosmic, TCGA, CGC genes) were first converted to
the currently approved HGNC gene symbols using the
gene nomenclature of HGNC, downloaded on August 26,
2014. Because of small differences in the column names of
the TCGA maf files (related to the centre that created the
file), they were first converted to a uniform format as spe-
cified in the breast cancer (2.5.3) file. Only primary
tumour samples were selected from these files.
When results were compared, they were first checked for
normality using the Shapiro-Wilk test. In case of normal
distribution the student t tests or ANOVA was used for
data comparison and mean values were reported, otherwise
the Wilcoxon-signed rank test was used and median values
were reported. False discovery rate correction was always
performed using the Benjamini-Hochberg method [19].
Results
Detection of mutational hot spots in the COSMIC
database
Because it is difficult to detect clustering mutations and
hence mutational hot spots across tumour samples in
small-sized datasets, SomInaClust uses prior information
regarding these gene-specific hot spots. This information
is calculated from a large reference database.
In this study we used COSMIC (v71) as a reference.
This database is the most complete database of somatic
mutations in cancer currently available [17], containing
data from 257,740 samples with a total number of
2,726,304 mutations, occurring in 20,269 genes. A total
number of 1,885 hot spots were detected in 867 genes,
with a median number of 1 and a maximum number of
113 hot spots per gene (Additional file 3: Table S2).
Mutation clusters (hot spots) were identified in both
OGs (e.g. PIK3CA, EGFR, AKT1) and TSGs (e.g. TP53,
PTEN, CDKN2A) (Figure 1). The identified mutational
hot spots included many well-studied oncogenic muta-
tions such as the PIK3CA’s E542K mutation (CDS pos-
ition 1624 and 1625), the AKT’s E17K mutation (CDS
position 49), and the EGFR’s L858R mutation (CDS pos-
ition 2573) (Additional file 3: Table S2).
When the genes that are present in the CGC list (v71)
were used as benchmark evaluation, 75% of CGC genes
with detected clusters were OGs, while 25% were TSGs. Al-
though these numbers and examples indicate that, as ex-
pected, for both OGs and TSGs significant clusters could
be detected, the mutation pattern for both types was clearly
different. For the known OGs, 25% (median) of all muta-
tions were clustering mutations, while for the known TSGs,
this was only 9% (p < 0.001). The opposite pattern was
Figure 1 Observed mutation patterns for known cancer genes in the COSMIC reference database. Visualization of missense (blue), protein-truncating
(green) and silent mutations (black) on the EGFR gene (A) as an example of a typical oncogene and the PTEN gene (B) as an example of a typical tumour
suppressor gene. Hot spots (red) indicate gene positions where a significant clustering of mutations was detected by SomInaClust across tumour samples.
(C) and (D). Boxplots show the proportion of clustering (C) and protein-truncating (D)mutations for known oncogenes (OG) and tumour suppressor genes
(TSG) for which hot spots were detected.
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all mutations for OGs and TSGs respectively (p < 0.001))
(Figure 1).
These results confirm the different mutation patterns
between OGs and TSGs across samples: OGs mainly
contain clustering missense mutations, while TSGs also
contain a high number of protein-truncating mutations.
Identification of driver genes in TCGA cancer data
As the breast cancer dataset is one of the most extended
and best characterized TCGA datasets [9], this study
mainly focuses on breast cancer. The results from 8 other
solid cancers are discussed in less detail and given in sup-
plementary tables and figures.
Using the somatic mutation TCGA data from 772 pri-
mary breast tumours, containing 47,114 mutations occur-
ring in 15,767 genes, SomInaClust identified 51 (0.3%)
putative driver genes (Additional file 4: Table S3). Some of
these genes were detected based on their high number ofmutations located at mutational hot spots and hence high
OG mutation contribution to the qDG value (e.g.
PIK3CA, AKT1). Others were detected based on their
high number of protein-truncating mutations and hence
high TSG mutation contribution to the qDG value (e.g.
GATA3, MAP3K1). For a third group of genes, both types
of mutations contributed to their significant qDG values
(e.g. TP53) (Figure 2). These results confirm the comple-
mentarity of using both OG and TSG mutation patterns
in the identification of putative driver genes. Indeed, if
only the qOG or qTSG values would be used for driver
gene identification (based on the proportion of clustering
mutations or protein-truncating mutations respectively)
several cancer genes would have remained undetected
(Additional file 5: Figure S2).
Some of the identified genes (e.g. TP53, PIK3CA,
GATA3) are known to be frequently mutated driver
genes in breast cancer [9]. However, SomInaClust also
prioritized driver genes that are less frequently mutated
Figure 2 Top 10 putative driver genes identified in breast cancer. Pyramid plot showing the top 10 putative driver genes retrieved by SomInaClust on the
TCGA breast cancer dataset and ranked according to their increasing q values. The OG scores are visualized on the left and the TSG scores on the right.
Dotted lines indicate cut-offs for classification as oncogene or tumour suppressor gene.
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CDKN1B (7 mutations, representing less than 1% of all
mutations across samples) (Additional file 6: Figure S3A).
The opposite is true for other genes, like TTN, MUC4
and RYR2, which are amongst the most frequently mu-
tated genes in breast cancer, but were clearly deprioritized
by SomInaClust (Additional file 6: Figure S3B).
For the other 8 solid cancers that were analysed by
SomInaClust, between 3 (ovarian cancer) and 343 (colon
cancer) putative driver genes were identified (Additional
file 7: Figure S4 and Additional file 4: Table S3).
SomInaClust accurately distinguishes oncogenes from
tumour suppressor genes
Based on the Vogelstein’ method we assume that at least
20% of the mutations occurring in OGs are located in
mutational hot spots (i.e. have an OG score equal or
higher than 20), whereas in TSGs at least 20% of the
mutations are protein-truncating mutations (i.e. have a
TSG score equal or higher than 20) [1]. Using this criter-
ion, all putative driver genes were classified based on
their OG and TSG scores. The classification accuracy
can be estimated for the genes that belong to the CGC
gene list, assuming that OGs are dominant and TSGs re-
cessive cancer genes [4]. Based on this assumption, 90%
(19 out of 21) of the candidate breast cancer genes, for
which information is available in the CGC list, were cor-
rectly classified. These genes included both well-known
oncogenes such as PIK3CA, AKT1 and ERBB2 and well-
known tumour suppressor genes such as TP53, PTEN
and MAP3K1 (Additional file 4: Table S3). The only 2genes that were not classified correctly were RUNX1 (a
dominant gene classified as TSG) and DNMT3A (a re-
cessive gene classified as OG).
After pooling the results of all 9 cancers together, the
overall classification accuracy was 81%. From the genes
classified as OGs, 89% were predicted correct (34 out of
38). For the predicted TSGs this was 78% (91 out of
117) (Additional file 8: Table S4). This lower predictive
value of TSG classified genes is for the major part ex-
plained by genes having high TSG scores and low OG
score (Figure 3). Examples of these genes are NOTCH1,
NOTCH2 and RUNX1 (Additional file 4: Table S3).
SomInaClust is complementary to other candidate driver
gene identification methods
Using the CGC list as a benchmark set for known cancer
genes, it is possible to calculate the CGC enrichment, i.e.
the proportion of the candidate driver genes that belong to
the CGC list. When the putative driver genes retrieved with
SomInaClust were ranked based on their (increasing) q
values, a clear CGC gene enrichment was found for the top
ranked genes for all 9 tumour types analysed (Figure 4A
and Additional file 9: Figure S5). On average 78.9%, 48.9%
and 24.1% of the top 10, 30 and 100 selected genes are
known as cancer genes according to the CGC list
(Figure 4B). A comparison of these CGC enrichment re-
sults with the results obtained by similar driver gene iden-
tification methods (i.e. MutSigCV, OncodriveClust and
OncodriveFM), showed that the best CGC enrichments
for a given number of ranked genes were obtained with
SomInaClust (Figure 4B and Additional file 9: Figure S5).
Figure 3 Classification accuracy of SomInaClust on the pooled set of
putative driver genes in 9 solid cancers. TSG scores are plotted as a
function of OG scores for all genes that were 1) retrieved by SomInaClust
in the 9 solid cancers analysed and 2) present in the CGC list. Genes that
are known to be dominant are shown in red, while recessive genes are
shown in green. The legend indicates the cancer type and is shown on
the top right. Dashed lines indicate cut-offs for classification as oncogene
or as tumour suppressor genes. Genes in the lower right part are classified
as oncogenes, in the upper (left and right) part as tumour suppressor
genes, while genes in the lower left part are unclassified.
Figure 4 CGC enrichment of the genes identified in breast and other solid c
cancer data set by different methods and ranked according to their increasin
CGC genes (y-axis) was determined. (B) The average CGC gene proportion of
ranked genes by each method. Error bars indicate standard errors of the mea
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mutation’s frequency-based enrichment, sustaining the
relevance of the prioritization and deprioritization of that
was shown in Additional file 6: Figure S3.
Compared to the 51 genes retrieved by SomInaClust, the
3 alternative methods we compared our results with, re-
trieved respectively 60 (MutSigCV), 253 (OncodriveClust)
and 34 (OncodriveFM) putative driver genes on the breast
cancer dataset (Figure 5A). From these gene sets, thirteen
genes were retrieved by all 4 methods (Figure 5A). These
genes included not only well known cancer genes (e.g.
TP53, PTEN, AKT1) but also genes with a less clear
(breast) cancer association (e.g. RBMX, RBM5). All 4
methods were found to be highly complementary as several
genes were only retrieved by a single method i.e. 11 genes
were detected by SomInaClust only, 10 by MutSigCV, 196
by OncodriveClust and 7 by OncodriveFM (Figure 5A).
From these gene sets, 7 (64%), 4 (40%), 6 (3%) and 0 genes
correspond to known cancer genes respectively, according
to the CGC gene list (Figure 5B). The 7 CGC genes that
were detected by SomInaClust only included well-known
(germline) cancer genes such as BRCA1, MEN1 and NF1.
The complementarity of the 4 methods is further supported
by the fact that some known cancer genes (e.g. EP300, LIFR
and BCL9) were not detected by any individual method,
but could be detected by the combination of all methods
(Figure 5B). The results of the comparison of the putative
driver genes retrieved in the 8 other solid cancers are
shown in Additional file 10: Figure S6.ancers. (A) Putative driver genes were detected on the TCGA breast
g q values. For each 1–100 top ranked genes (x-axis) the proportion of
all 9 solid cancers that were analysed for the highest 10, 30 and 100
n. The methods are indicated in the legend on the bottom of the figure.
Figure 5 Putative breast cancer genes retrieved by 4 different methods. (A) Venn diagrams indicating the total number of putative breast cancer driver
genes retrieved by 4 different methods (method names are indicated on the diagram). (B) Comparison of the significance levels of the genes that were
detected by the 4 methods. Genes are ranked according to the product of the q values of the 4 methods together (indicated by the last “combination”
column). The colour scale is shown on the bottom right with q values varying from 0.05 (yellow) to 1e-5 or higher (red). Blue boxes indicate
non-significant genes.
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To verify whether the retrieved genes are active in known
cancer pathways, a KEGG pathway enrichment analysis was
performed. This analysis showed that the identified putative
breast cancer driver genes are indeed active in pathways in-
volved in apoptosis, PI3K-AKT, MAPK and ERBB signalling
(Additional file 11: Table S5). Figure 6 summarizes the inter-
action between the identified genes in these pathways. For
all of these genes, their role in carcinogenesis (i.e. the evolu-
tion towards a selective growth advantage) can be directly
derived from the SomInaClust classification as a putative
OG or TSG, with the former leading to pro-proliferative or
anti-apoptotic effects and the latter to the opposite effects.
Interestingly, although some rarely mutated genes like
KRAS, ERBB2 and CDKN1B were identified by SomIna-
Clust and have obvious carcinogenic roles in the aforemen-
tioned pathways, also genes that remained below the
detection threshold (i.e. qDG> 0.05) had OG and TSG
scores showing a clear tendency towards a correct classifica-
tion, based on their signalling interactions (e.g. MAPK8).
Similar KEGG driver pathways were found for the
other 8 tumours that were analysed using SomInaClust(Additional file 11: Table S5) and for most of the genes
that are active in these signalling pathways, their pre-
dicted role (OG or TSG) is related to carcinogenesis.
Discussion
In this study we have introduced SomInaClust, a new can-
cer (driver) gene identification method that is based on
the observation that somatic driver mutations in cancer
tend to be inactivating (protein-truncating) and/or cluster
together across tumour samples. This mutation pattern is
further used to classify putative cancer genes in OGs or
TSGs. The method is based on a principle described by
Vogelstein et al. [1] and prioritizes driver genes by calcu-
lating a driver gene statistic (i.e. qDG-value).
SomInaClust uses prior information regarding muta-
tional hot spots and the background mutation rate. In this
study this prior information was determined from COS-
MIC, but any other large mutation database could have
been used for this purpose. Using such a large reference
database allows identifying hot spots that are impossible
to recover at the specific cancer tissue type level due to
the small size of these specific datasets (i.e. it is impossible
Figure 6 Signalling network of the putative breast cancer genes. The top-ranked genes that were detected on the breast cancer dataset were shown to be
primary involved in the PI3K and the MAPK pathways. Genes are coloured green when they were classified as putative tumour suppressor genes (TSG scores
≥20) or in red when classified as putative oncogenes (OG scores ≥20 and TSG scores <20). The genes indicated in grey were not found to be significant by
SomInaClust. Mutation frequencies and scores (OG score and TSG score respectively) are indicated below each gene. Arrows indicate stimulation, while
bar-headed lines indicate inhibition.
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present). As an alternative, more sophisticated methods
could have been used for the detection of these mutation
clusters (e.g. iPAC and GraphPac [24,25]), but, as these
depend on the availability of additional knowledge (e.g. re-
garding protein spatial structure information), we chose
for the more widely applicable statistical approach pre-
sented in this work. This approach was shown to identify
mutation clusters in 867 genes, including most well-
known oncogenic mutations (e.g. in oncogenes like EGFR,
PIK3CA and AKT1).
SomInaClust was shown to identify candidate driver genes
with high accuracy. Even genes that are mutated in less than
1% of all sequenced tumour samples were detected. This is
exemplified by the analysis of the breast cancer dataset, from
which the well-known but rarely mutated cancer genes
CDKN1B (7 mutations out of 772 samples), KRAS (6 muta-
tions) and MEN1 (5 mutations) were identified. On the
other hand, the method was also shown to deprioritize fre-
quently mutated genes like TTN, MUC4 and RYR2, which
have been described as “artefacts” by others [10,26].
We compared the results obtained with SomInaClust
with those obtained by the previously published driver
gene prioritization methods MutSigCV, OncodriveFM and
OncodriveClust [11,14,15] on the same dataset. Genes
identified by SomInaClust as well as by the other investi-
gated methods not only included well-known cancer
genes, but also genes without a previously described can-
cer link (e.g. RBMX and TBM5 on the breast cancer data-
set). As every individual method uses a partially differentapproach (different background mutation models, muta-
tion clustering, functional impact) to prioritize drivers, it
is very likely that genes identified by multiple methods are
truly involved in (subgroups of) breast carcinogenesis.
The analysis in this study also confirmed the known com-
plementarity of the different driver gene prioritization
methods [12,27]. Indeed, every single method also identi-
fied unique gene sets (i.e. genes identified by one single
method). Although some of these genes probably repre-
sent false positive results, it is interesting to note that
SomInaClust contains amongst its predicted driver genes,
the highest proportion (64%) of previously described can-
cer (CGC) genes. In line with these findings, the SomIna-
Clust driver gene prioritization, as quantified via a CGC
enrichment analysis, was found to be superior to the other
methods that were examined.
Of all the investigated methods, SomInaClust was the
only method to identify 10 genes (e.g. BRCA1, ATM,
NF1) based on their higher than expected number of
protein-truncating mutations. This higher sensitivity to-
wards the detection of these well-known tumour suppres-
sor genes is likely explained by the fact that SomInaClust
takes into account all protein-truncating mutations, rather
than just searching for clustering mutations, which is done
by e.g. OncodriveClust [14].
Apart from the methods mentioned here, several
other driver gene prioritization methods have been pub-
lished (for a review see [12]). However, while the
methods that were evaluated in this study only require a
mutation file to be run, most of the other available
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MuSiC [13]).
Under the assumption that OGs become carcinogenic
by dominant mutations (i.e. by mutations in either allelic
variants of a gene), and TSGs by recessive mutations (i.e.
both allelic variants of a gene need to be mutated) [4], the
classification accuracy could be calculated for the putative
driver genes that were present in the CGC list. This re-
sulted in an overall classification accuracy of 81% (positive
predictive values of 89% for OGs and 78% of TSGs) for
the 9 tumours that were analysed in this study. The lower
predictive values for TSGs may be an underestimation.
Firstly, because it has been shown that some genes have
dual roles in cancer, in which they function as an OG in
one cancer type but as a TSG in another. This is exempli-
fied by NOTCH1, which has been described as a domin-
ant (and hence OG) gene in leukaemia, but was shown to
be a TSG in solid cancers as well [28]. Also in this study,
NOTCH1 was (wrongly?) classified as a TSG in head and
neck cancer, possibly explaining part of the misclassified
genes and indicating that the true classification accuracy
is likely to be higher. Secondly it has been demonstrated
that the assumption that TSGs act in a recessive way does
not always hold. Indeed, haploinsufficiency has been
shown for several TSGs, i.e. genes that result in a growth
advantage even when only one allele is defective [29].
Interestingly, this has also been shown for RUNX1, one of
the only 2 putative driver genes that were misclassified in
breast cancer [30].
The highest number of putative driver genes was found
in colon (343) and uterine cancer (308), while in ovarian
cancer only few genes were retrieved. This may be related
to the recently described pan-cancer classes, with the first 2
cancers belonging to the M class (dominated by mutations)
and the last one belonging to the C class (dominated by
copy number variations) [31]. Interestingly, a lot of rarely
mutated putative driver genes that were detected in breast
cancer have been described as copy number amplifications
(e.g. ERBB2) or deletions (e.g. RB1, MEN1, PTEN) before
[9]. The identification of these genes as being mutated at
the individual patient level might be crucial for personalized
treatment choices.Conclusions
In this study a method was presented that was shown to
be able to detect candidate cancer driver genes based on
somatic mutation patterns of inactivating and clustering
(SomInaClust). The method was shown to be comple-
mentary to existing similar-purpose methods with the
additional advantages that it has a higher sensitivity, also
for very rare (<1%) mutations, and it accurately classifies
the detected genes into putative oncogenes and tumour
suppressor genes.The method, example files, reference files and infor-
mation on how to use the method are implemented as
an R package, which is freely available at http://bioinfor-
matics.intec.ugent.be/sominaclust.Additional files
Additional file 1: Figure S1. Outline of the SomInaClust method. For
each gene the total number of mutations is counted across all tumour
samples in a reference database (step 1: reference step) or a test dataset
(step 2: gene detection step). Protein truncating mutations (i.e. nonsense
mutations or out-of-frame indels) are referred to as TSG mutations. Other
mutations (i.e. missense mutations or in-frame indels are referred to as
OG mutations). N: the (uncorrected) number of silent (Nsil), OG (NOG) and
TSG (NTSG) mutations. n: the number of OG (nOG), TSG (nTSG) and total
number (ntot) of mutations, multiplied with the gene-specific OG/TSG
correction factor. k: number of OG mutations located at the same CDS
position (kOG) or at mutational hot spot locations (khOG), multiplied with
the gene-specific OG correction factor. See main text (Methods section)
for further explanation.
Additional file 2: Table S1. Overview of all theoretically possible
mutations occurring in non-stop codons. Each of 61 non-stop codons
can theoretically mutate in 9 different codons (3 possible mutations for
each nucleotide), implying a total number of 549 possible mutations.
From these 549 mutations, 134 can be classified as silent, 392 as missense
and 23 as nonsense. Mutation types are indicated with 0 (absent) or 1
(present). nt1, nt2 and nt3: first, second and third nucleotide of the
corresponding codon.
Additional file 3: Table S2. Overview of genes and their identified
mutational hot spots in the COSMIC v71 database. The first tab shows
the genes that contain at least 1 identified mutational hot spot. Genes
are ranked according to their number of detected hot spots. Columns
represent gene names, number of detected hot spots, size of the
smallest mutation cluster and number of mutations respectively. The
second tab shows the CDS and amino acid positions of all the identified
mutational hot spots.
Additional file 4: Table S3. Putative driver genes detected by
SomInaClust in 9 different cancer types. Genes are ranked according to
their increasing q values. Columns represent gene names, number of
mutations, q value, OG score, TSG score, classification (OG or TSG) and
CGC class (dominant or recessive, NA means the gene does not belong
to the CGC list). The following cancer types were analysed (tab names):
bladder cancer (BLCA), breast cancer (BRCA), colon cancer (COAD),
glioblastoma multiforme (GBM), head and neck squamous cell cancer
(HNSC), lung squamous cell cancer (LUSC), ovarian cancer (OV), rectal
cancer (READ) and uterine cancer (UCEC).
Additional file 5: Figure S2. Complementary role of clustering and
protein-truncating mutations in the detection of putative cancer genes.
Comparison of the significance levels of the genes that were detected by
the SomInaClust method between using qDG (default), using only the
clustering mutations (i.e. OG mutations, yielding qOG) and using only the
protein-truncating mutations (i.e. TSG mutations, yielding qTSG). Genes
are ranked on increasing qDG values and only the first 50 genes are
shown. The colour scale is shown on the bottom right with q values
varying from 0.05 (yellow) to 1e-5 or higher (red). Blue boxes indicate
non-significant genes. The following cancer types were analysed as
indicated on top of each figure: bladder cancer (BLCA), breast cancer
(BRCA), colon cancer (COAD), glioblastoma multiforme (GBM), head and
neck squamous cell cancer (HNSC), lung squamous cell cancer (LUSC),
ovarian cancer (OV), rectal cancer (READ) and uterine cancer (UCEC).
Additional file 6: Figure S3. Prioritization and deprioritization of
putative cancer genes by SomInaClust. Correlation between SomInaClust
(y-axis) and mutation frequency (x-axis) ranks in breast cancer. (A) Focus
on the first 20 SomInaClust ranked genes. (B) Focus on the first 20
frequency ranked genes. Genes that are clearly (de)prioritized are
indicated and named in red.
Van den Eynden et al. BMC Bioinformatics  (2015) 16:125 Page 11 of 12Additional file 7: Figure S4. Putative driver genes retrieved in 8 solid
cancers. Pyramid plots showing the top (20) putative driver genes retrieved by
SomInaClust in 8 TCGA cancers: bladder cancer (BLCA), colon cancer (COAD),
glioblastoma multiforme (GBM), head and neck squamous cell cancer (HNSC),
lung squamous cell cancer (LUSC), ovarian cancer (OV), rectal cancer (READ)
and uterine cancer (UCEC). Genes are ranked according to increasing q values.
The 20 highest ranked genes are shown, or less when fewer genes were
found significant. The OG scores are visualized on the left and the TSG scores
on the right. Dotted lines indicate cut-offs for classification as oncogene or
tumour suppressor gene.
Additional file 8: Table S4. Classification results. Contingency tables
showing the classification results of all 9 individual cancers and the
pooled set of tumours. The following cancer types were analysed:
bladder cancer (BLCA), breast cancer (BRCA), colon cancer (COAD),
glioblastoma multiforme (GBM), head and neck squamous cell cancer
(HNSC), lung squamous cell cancer (LUSC), ovarian cancer (OV), rectal
cancer (READ) and uterine cancer (UCEC).
Additional file 9: Figure S5. CGC enrichment of the top 100 ranked
genes in 8 solid cancers. CGC enrichment plots for 8 different TCGA
cancers: bladder cancer (BLCA), colon cancer (COAD), glioblastoma
multiforme (GBM), head and neck squamous cell cancer (HNSC), lung
squamous cell cancer (LUSC), ovarian cancer (OV), rectal cancer (READ)
and uterine cancer (UCEC). Genes are ranked according to increasing q
values and for each top 1–100 ranked genes (x-axis) the proportion of
CGC genes (y-axis) is determined. Five different methods were compared
as indicated in the legend on the top right of each plot.
Additional file 10: Figure S6. Putative driver genes retrieved by 4
different methods in 8 solid cancers. (A) Venn diagrams indicating the
total number of putative cancer driver genes retrieved by 4 different
methods. (B) Comparison of the significance levels of the genes that
were detected by the 4 methods. Genes are ranked according to the
product of the q values of the 4 methods together (indicated by the last
“Combination” column). The colour scale is shown on the bottom right
with q values varying from 0.05 (yellow) to 1e-5 or higher (red). Blue
boxes indicate non-significant genes. The following cancer types were
analysed as indicated on top of each figure: bladder cancer (BLCA), colon
cancer (COAD), glioblastoma multiforme (GBM), head and neck squamous
cell cancer (HNSC), lung squamous cell cancer (LUSC), ovarian cancer
(OV), rectal cancer (READ) and uterine cancer (UCEC).
Additional file 11: Table S5. KEGG pathway enrichment analysis of the
putative driver genes. Pathways are ranked according to increasing q
values. Columns represent cancer type, pathway IDs, pathway names and
the enrichment q values respectively. The following cancer types were
analysed (tab names): bladder cancer (BLCA), breast cancer (BRCA), colon
cancer (COAD), glioblastoma multiforme (GBM), head and neck
squamous cell cancer (HNSC), lung squamous cell cancer (LUSC), ovarian
cancer (OV), rectal cancer (READ) and uterine cancer (UCEC).Competing interests
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